SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX

Core Viewpoint - A class action lawsuit has been filed against Kyverna Therapeutics, Inc. for alleged securities fraud and unlawful business practices [1][3]. Group 1: Class Action Details - The class action lawsuit is initiated by Pomerantz LLP, and shareholders who acquired DMC securities during the Class Period can request to be appointed as Lead Plaintiff by February 7, 2025 [2][3]. - A copy of the Complaint is available at Pomerantz's website [2]. Group 2: Company Background and IPO - Kyverna Therapeutics conducted its initial public offering (IPO) on February 8, 2024, offering 14.5 million shares at a price of $22.00 per share [4]. - On the same day, the company disclosed adverse data from a clinical trial, leading to a significant drop in stock price [5]. Group 3: Stock Performance - Following the adverse disclosures, Kyverna's stock price fell by $4.91, or 34%, closing at $9.53 per share on June 14, 2024 [5].